Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report released on Thursday morning,Benzinga reports. Needham & Company LLC currently has a $6.00 price objective on the stock.

A number of other research analysts also recently issued reports on the stock. Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Trading Down 1.9 %

NASDAQ TSHA opened at $1.59 on Thursday. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The firm has a 50 day simple moving average of $1.68 and a 200-day simple moving average of $1.98. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The firm has a market cap of $325.86 million, a price-to-earnings ratio of 2.52 and a beta of 0.93.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $2.05 million. Equities research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors have recently modified their holdings of TSHA. Creative Planning acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at $28,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after acquiring an additional 17,446 shares during the period. Quantum Private Wealth LLC increased its holdings in shares of Taysha Gene Therapies by 5.1% in the 3rd quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock valued at $1,543,000 after acquiring an additional 37,096 shares during the period. Privium Fund Management B.V. increased its holdings in shares of Taysha Gene Therapies by 21.8% in the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock valued at $241,000 after acquiring an additional 21,500 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at $416,000. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.